Image Place holder

Shahla Bari, MD

Specialty: Hematology/Oncology
Program: Cutaneous Oncology


Cancer Focus: Melanoma

Dr. Shahla Bari is an Assistant Member in the Department of Cutaneous Oncology. Dr. Bari received her MD degree from Patna Medical College, India. She completed an Internal Medicine residency at Morehouse School of Medicine, Atlanta, GA. Following her residency, she was an NIH Research Scholar for “Cancer Health Disparities Training and Research Education” (U54 program). Dr. Bari most recently completed a Hematology/Oncology Fellowship at Moffitt Cancer Center and the University of South Florida. Dr. Bari’s clinical interest and focus is in immuno-oncology, including ancestry-based disparities in immunotherapy treatment outcomes. Her research interest is in the role of microbial metabolomics in understanding the mechanism of immunotherapy resistance, and in the development of metabolomics based immuno-imaging. She was a recipient of the prestigious ASCO Young Investigator Award in 2021, under the mentorship of Dr. Conejo-Garcia and Dr. Brandon Manley. Dr. Bari will have a joint appointment in the Cellular Immunotherapy Program with a clinical focus on adoptive cellular therapy in cutaneous malignancies

Education & Training

Participating Trials

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer. 2022 Jan.22(1):101. Pubmedid: 35073876. Pmcid: PMC8787935.
  • Crowder SL, Hoogland AI, Welniak TL, LaFranchise EA, Carpenter KM, Li D, Rotroff DM, Mariam A, Pierce CM, Fischer SM, Kinney AY, Dong-Binh Tran T, Rastegari F, Berry DL, Extermann M, Kim RD, Tometich DB, Figueiredo JC, Muzaffar J, Bari S, Turner K, Weinstock GM, Jim HSL. Metagenomics and chemotherapy-induced nausea: A roadmap for future research. Cancer. 2022 Feb.128(3):461-470. Pubmedid: 34643945. Pmcid: PMC8776572.
  • Bari S, Boulware D, Li J, Loftus L, Soyano Muller A, Jameel Z, Khong H, Czerniecki BJ, Costa RLB. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Breast Cancer (Dove Med Press). 2022 Aug.14:199-210. Pubmedid: 35967746. Pmcid: PMC9365325.
  • Bari S, Muzaffar J, Eroglu Z. Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?. Ther Adv Med Oncol. 2022 Apr.14. Pubmedid: 35478991. Pmcid: PMC9036333.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Bari S, Chineke I, Darwin A, Umar A, Jim H, Muzaffar J, Kucuk O. Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. Integr Cancer Ther. 2021 Jan.20. Pubmedid: 34923869. Pmcid: PMC8724982.
  • Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion. 2019 Jun.59(6):1907-1910. Pubmedid: 30768787.
  • Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. J Oncol. 2019 Jan.2019:2989048. Pubmedid: 31275380. Pmcid: PMC6582789.
  • Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Corrigendum to "Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer". J Oncol. 2019 Aug.2019:7921582. Pubmedid: 31531021. Pmcid: PMC6719266.
  • Wallace L, Cherian AM, Adamson P, Bari S, Banerjee S, Flood M, Simien M, Yao X, Aikhionbare FO. Comparison of Pre- and Post-translational Expressions of COXIV-1 and MT-ATPase 6 Genes in Colorectal Adenoma-Carcinoma Tissues. J Carcinog Mutagen. 2018 Nov.9(2). Pubmedid: 30393577. Pmcid: PMC6214464.
  • Nguyen TC, Bajwa R, Bari S, Ali A, Paul Skelton W, Federico RA, Bishnoi R, Wray JW, Zlotecki RA, Dang LH, Muzaffar J. Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. Oxf Med Case Reports. 2018 Jan.2018(1):omx078. Pubmedid: 29340160. Pmcid: PMC5761507.
  • Farrar JE, Quarello P, Fisher R, O'Brien KA, Aspesi A, Parrella S, Henson AL, Seidel NE, Atsidaftos E, Prakash S, Bari S, Garelli E, Arceci RJ, Dianzani I, Ramenghi U, Vlachos A, Lipton JM, Bodine DM, Ellis SR. Exploiting pre-rRNA processing in Diamond Blackfan anemia gene discovery and diagnosis. Am J Hematol. 2014 Oct.89(10):985-991. Pubmedid: 25042156. Pmcid: PMC4332597.


Title: Microbial Metabolome as a Biomarker of Loss of Response to Immunotherapy in Metastatic Melanoma
Sponsor: Moffitt Cancer Center
PI: Bari, S.
Title: Microbial metabolome is a predictor of TIL efficacy in metastatic melanoma.
Sponsor: Moffitt Cancer Center
PI: Bari, S.

Patient Comments
Overall Satisfaction

6 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments